Babylon closes US business as rescue merger deal fails
pharmaphorum
AUGUST 10, 2023
Babylon closes US business as rescue merger deal fails Phil.Taylor Thu, 10/08/2023 - 09:30 Bookmark this
us business 
Obesity cost US businesses $425.5bn in 2023
Pharmaceutical Technology
FEBRUARY 29, 2024
An Eli Lilly-sponsored GlobalData report finds that obese workers had $6,472 higher annual in medical and economic costs.
52 Join 33,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Shubh Goel, VP, Head of Immuno-Oncology and Gastrointestinal Tumors Franchise, US Oncology Business Unit, AstraZeneca, Discusses Positive Results From Phase III Trial In Patients With HCC
PharmExec
FEBRUARY 2, 2024
In an interview with Pharm Exec Associate Editor Don Tracy, Shubh Goel, Head of Immuno-Oncology and Gastrointestinal Tumors, US Oncology Business Unit, AstraZeneca, provides her thoughts on the success of the trial.
52 
STAT+: Pharmalittle: We’re reading about Takeda restructuring, Pfizer settling Zantac suits, and more
STAT
MAY 9, 2024
Rise and shine, everyone, another busy day is on the way. We can tell because countless birds are chirping outside our window, the pace of motor vehicles passing by our window is picking up, and the official mascots are busy foraging for snacks on the official grounds. As always, you are invited to join us.
203 
STAT+: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more
STAT
MARCH 14, 2024
Rise and shine, everyone, another busy day is on the way. Please do join us. government scrutiny of the biotech and other Chinese companies , STAT tells us. … The Biotechnology Innovation Organization, the industry trade group, is cutting ties with China’s WuXi in response to increasing U.S.
Biosimilars 229
229 Biosimilars 229
229 
Philips Respironics Finalizes Consent Decree Regarding Business Operations in the US with Department of Justice, FDA
PharmExec
APRIL 10, 2024
Decree comes amid the FDA’s 2021 inspection of Philips’ Murrysville facility and the subsequent voluntary recall of its sleep and respiratory care devices.
52 
STAT+: Pharmalittle: We’re reading about slow uptake of an Alzheimer’s drug, an opioid lawsuit, and more
STAT
FEBRUARY 14, 2024
We are doing just fine, thank you, especially since the middle of the week is upon us. And what better way to make the time fly than to keep busy. Food and Drug Administration fully approved a Biogen treatment for Alzheimer’s disease, only about 2,000 patients are taking the medicine nationwide , The Boston Globe tell us.
Biosimilars 213
213 Biosimilars 213
213 
STAT+: Pharmalittle: We’re reading about BIO’s China challenge, Zepbound shortages, and more
STAT
APRIL 18, 2024
Rise and shine, everyone, another busy day is on the way. We recall a bit of insight from the Morning Mayor, who taught us that “Every new day should be unwrapped like a precious gift.” biotechs from doing business with the Chinese behemoth , STAT says. Our choice today is pistachio creme.
223 
In new order on AI, Biden is scrambling to catch up to emerging risks in health care
STAT
OCTOBER 30, 2023
President Joe Biden ordered the nation’s leading health agencies on Monday to develop a plan for regulating artificial intelligence tools already widely in use within hospitals, insurance companies, and other health-related businesses.
Hospitals 296
296 Hospitals 296
296 
STAT+: Pharmalittle: We’re reading about a Senate probe into Novo pricing, a new UTI antibiotic, and more
STAT
APRIL 25, 2024
Rise and shine, everyone, another busy day is on the way. We can tell because countless birds are chirping outside our window, the pace of motor vehicles passing by is picking up, and the official mascots are busy foraging for snacks on the official grounds. As for us, we are engaged in the usual ritual of brewing cups of stimulation.
Packaging 207
207 
STAT+: Pharmalittle: We’re reading about a Vertex pain pill, an abortion pill hearing, and more
STAT
JANUARY 30, 2024
As for us, we are as busy as ever hunting and gathering items of interest. We trust you have your own busy agendas. So join us as we hoist the ever-present cup of stimulation — our choice today is cinnamon sticky bun — and attack the fast-growing to-do list.
Diabetes 207
207 
STAT+: Pharmalittle: We’re reading about biotech startups, Pfizer’s RSV vaccine, and more
STAT
APRIL 9, 2024
Rise and shine, everyone, another busy day is on the way. We can tell because countless birds are chirping outside our window, the pace of motor vehicles passing by is picking up, and the official mascots are busy foraging for snacks on the official grounds. As for us, we are engaged in the usual ritual of brewing cups of stimulation.
Vaccines 161
161 Vaccines 161
161 
STAT+: Pharmalittle: Weight loss drugs are being paired with bariatric surgery; Carl Icahn plans to oust Illumina directors
STAT
DECEMBER 19, 2023
As for us, we are as busy as ever hunting and gathering items of interest. We trust you have your own busy agendas. So join us as we hoist the ever-present cup of stimulation — our choice today is gingerbread — and attack the fast-growing to-do list.
237 
Opinion: Psychiatrists like us cannot keep up with their inboxes
STAT
AUGUST 28, 2023
But if you’re working in a clinic setting (like one of us, Jessi, is currently, and the other, Simone, has done previously), one thing is for sure: You’re busy. When you’re a psychiatrist, there’s no such thing as a typical day. Read the rest…
222 
Shakeup at BenevolentAI continues with job, programme cuts
pharmaphorum
APRIL 23, 2024
BenevolentAI is embarking on another round of job losses, closing its US office, and shelving its software-as-a-service business to extend its cash reserves into the third quarter of 2025.
101 
STAT+: Up and down the ladder: The latest comings and goings
STAT
SEPTEMBER 22, 2023
Share the news with us, and we’ll share it with others. Send us your changes, and we’ll find a home for them. Previously, he worked at Nkarta, where he was chief financial and business officer. Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot?
213 
STAT+: Pharmalittle: AbbVie buys Immunogen, maker of targeted cancer drugs; Novo sues two more compounders
STAT
NOVEMBER 30, 2023
Rise and shine, everyone, another busy day is on the way. As for us, we are dutifully firing up the coffee kettle to brew another cup of needed stimulation. Please feel free to join us. We hope you find these useful and have a smashing day. Our choice today is blueberry cobbler. Our choice today is blueberry cobbler.
Compounding 229
229 
Back to school for biotech, Biogen’s potential pivot, & Illumina’s next chapter
STAT
SEPTEMBER 7, 2023
Josh Schimmer and Eric Schmidt, two longtime analysts teaming up at Cantor Fitzgerald, join us for a back-to-school conversation as biotech enters the busy back third of 2023. We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast.
217 
STAT+: Pharmalittle: We’re reading about Wegovy and Ozempic sales, rising pharma layoffs, and more
STAT
MAY 2, 2024
Rise and shine, everyone, another busy day is on the way. We recall a bit of insight from the Morning Mayor, who taught us that “Every new day should be unwrapped like a precious gift.” Sadly, gray skies are hovering over the Pharmalot campus again, but our spirits remain sunny, nonetheless.
181 
STAT+: Up and down the ladder: The latest comings and goings
STAT
MARCH 1, 2024
Share the news with us, and we’ll share it with others. That’s Send us your changes, and we’ll find a home for them. Previously, she worked at Kira Pharma, where she was head of business development and strategy. Hired someone new and exciting? Promoted a rising star? Don’t be shy.
190 
Q&A With Court Horncastle, Vice President and Business Unit Head, Respiratory, US Commercial for GSK
PharmExec
AUGUST 5, 2022
Court Horncastle discusses how his career led him to work with treating COPD and asthma.
111 
STAT+: Pharmalittle: We’re reading about worries over a Novo deal, a PBM bill, and more
STAT
FEBRUARY 7, 2024
The middle of the week is upon us. And what better way to make the time fly than to keep busy. Meanwhile, do keep us in mind if you hear anything interesting. Rise and shine, everyone. Have heart, though. You made it this far, so why not hang on for another couple of days, yes? Consider the alternatives, if you must.
Diabetes 236
236 Diabetes 236
236 
Boundless Bio files IPO, and other biotech financings
pharmaphorum
MARCH 7, 2024
Boundless Bio made a play to become the seventh US biotech to seek a public listing in 2024, ending a brief hiatus in IPO activity after a busy start to the year.
102 
STAT+: Pharmalittle: We’re reading about Sanofi licensing Novavax’s Covid shot, Moderna’s RSV vaccine, and more
STAT
MAY 10, 2024
Sales of Novavax’s Covid shot have sputtered along, and last year, the Maryland-based company warned that it may not be able to stay in business. An ambitious effort to cure HIV with CRISPR genome editing fell short in an early clinical trial, STAT informs us.
Vaccines 183
183 Vaccines 183
183 
Community health workers, experts in the in-between, fight for their place in the system
STAT
AUGUST 7, 2023
NEW YORK — A nurse supervisor at Montefiore Comprehensive Health Care Center in the Bronx was delivering her start-of-shift updates and mantras — “Covid is not finished with us … clean, clean, clean!”— ”— to the clinicians and administrative staff bunched up nearby.
Hospitals 244
244 Hospitals 244
244 
STAT+: Pharmalittle: We’re reading about a 486% drug price hike, AstraZeneca CEO pay, and more
STAT
APRIL 10, 2024
We are doing just fine, thank you, especially since the middle of the week is upon us. And what better way to make the time fly than to keep busy. Now, though, the time has come to get busy. After all, we have made it this far, so we are determined to hang on for another couple of days. And why not?
Drug Pricing 201
201 Drug Pricing 201
201 
STAT+: Pharmalittle: We’re reading about an AstraZeneca deal, a WHO pandemic pact, and more
STAT
MARCH 19, 2024
Rise and shine, everyone, another busy day is on the way. As for us, we are engaged in the usual rituals, starting with brewing cups of stimulation. Please feel free to join us. Already, the official mascots are racing about the Pharmalot campus in search of breakfast and a steady stream of traffic can be heard nearby.
238 
STAT+: Protesters slam health insurance lobby for Medicare Advantage coverage restrictions
STAT
JUNE 27, 2023
The protesters were crammed into an already busy part of the city. The protesters, organized by a group called People’s Action, left messages on the sidewalk in chalk that included “You make us sick,” and “for-profit health ‘care’ killed my mom.”
Drug Pricing 292
292 Drug Pricing 292
292 
STAT+: Pharmalittle: Pharma wins changes in bill concerning accelerated approval; pharmacy chains restrict purchases of pediatric pain relievers
STAT
DECEMBER 20, 2022
Rise and shine, everyone, another busy day is on the way. As for us, we are busy with the usual tasks, namely firing up the coffee kettle to make cups of stimulation. As for us, we are busy with the usual tasks, namely firing up the coffee kettle to make cups of stimulation. As always, you are invited to join us.
Labelling 218
218 Labelling 218
218 
STAT+: Pharmalittle: We’re reading about CVS dropping Humira coverage, pharma layoffs, and more
STAT
JANUARY 4, 2024
Rise and shine, everyone, another busy day is on the way. We will draw on a bit of insight from the Morning Mayor, who taught us that “Every new day should be unwrapped like a precious gift.” Sadly, gray skies are hovering over the Pharmalot campus right now, but our spirits remain sunny, nonetheless.
Biosimilars 268
268 
Listen: ChatGPT in medicine, a boom in weight loss pills, & Sarepta at the FDA
STAT
MAY 25, 2023
As hospitals and health care companies are racing to implement large language models like ChatGPT into their businesses, STAT reporter Casey Ross joins us to explain what experts want the world to know before embracing generative AI.
Hospitals 177
177 Hospitals 177
177 
STAT+: Pharmalittle: We’re reading about Amylyx pulling its ALS drug, GLP-1 drugs for Parkinson’s, and more
STAT
APRIL 4, 2024
As always, you are invited to join us. This is a busy world, is it not? And please do think of us when you hear something saucy. Our choice today is toasted coconut. Meanwhile, we are proud to present our latest list of interesting items for you to peruse. And there is much to review. So time to get cracking.
Diabetes 201
201 
Listen: Anti-science at the polls, a biotech odd couple, & the stakes of the midterms
STAT
OCTOBER 27, 2022
How is the music business like biotech investing? Our colleague Sarah Owermohle joins us to discuss how pandemic shutdowns, Covid-19 vaccines, and the prospect of arresting Anthony Fauci have become campaign rallying cries in midterm elections. Can Covid denialism get you elected?
Drug Pricing 208
208 
STAT+: Pharmalittle: Lilly diabetes drug back on shelves after two-month shortage; AbbVie sued for human rights violations over Humira pricing
STAT
FEBRUARY 22, 2023
The middle of the week is upon us. And what better way to make the time fly than to keep busy. Rise and shine, everyone. Have heart, though. You made it this far, so why not hang on for another couple of days, yes? So grab that cup of stimulation — our flavor today is mocha marshmallow — and get started.
Diabetes 196
196 
Listen: Pharma blockbusters, pandemic policy, & legal chicanery
STAT
FEBRUARY 2, 2023
STAT Washington correspondent Rachel Cohrs joins us to explain the looming end of Covid-19’s status as a federal emergency and what that does and doesn’t mean for public health. We also dig into the most interesting stories from a busy week of pharmaceutical earnings and discuss a legal setback for Johnson & Johnson.
183 
STAT+: Pharmalittle: Weight-loss drug ads pose new oversight challenge; will the new Bayer CEO split the company?
STAT
APRIL 6, 2023
Rise and shine, another busy day is on the way. We can tell because the official mascot is noisily bounding about the grounds in search of wildlife and Mrs. Pharmalot is busy putting the finishing touches on yet another feast that marks the observance of ancient traditions this week.
Packaging 201
201 
STAT+: Pharmalittle: AMA calls for obesity drug coverage; Covid rebound may be more common with Paxlovid than without
STAT
NOVEMBER 14, 2023
As for us, we are as busy as ever hunting and gathering items of interest. So join us as we hoist the ever-present cup of stimulation — our choice today is gingerbread — and attack the fast-growing to-do list. We trust you have your own hectic agendas.
Chemotherapy 247
247 Chemotherapy 247
247 
Listen: Sarepta’s pivotal moment, biotech’s big week, & the future of Covid boosters
STAT
APRIL 20, 2023
Our colleague Helen Branswell joins us to explain the latest news on Covid-19 boosters and the implications of a Marburg outbreak in Equatorial Guinea. We also break down the rest of the week’s biggest news in biopharma, including some billion-dollar deals and the retirement of perhaps the most storied executive in the business.
Vaccines 201
201 Vaccines 201
201 
STAT+: Pharmalittle: We’re reading about a CRISPR approval, selling meds directly to patients, and more
STAT
JANUARY 17, 2024
The middle of the week is upon us. And what better way to make the time fly than to keep busy. Meanwhile, do keep us in mind if you hear anything interesting. Have heart, though. You made it this far, so why not hang on for another couple of days, yes?
214 
STAT+: Pharmalittle: U.K. approves world’s first CRISPR-based medicine; FDA to review pricey cancer drug lacking confirmatory data
STAT
NOVEMBER 16, 2023
Rise and shine, everyone, another busy day is on the way. As for us, we are dutifully firing up the coffee kettle to brew another cup of needed stimulation. Please feel free to join us. We can tell because the official mascots are racing about the Pharmalot grounds and the parade of vehicles outside our window is picking up.
Drug Pricing 157
157 Drug Pricing 157
157 
STAT+: Pharmalittle: We’re reading about Wegovy supplies, Biogen ditching Aduhelm, and more
STAT
JANUARY 31, 2024
The middle of the week is upon us. And what better way to make the time fly than to keep busy. Meanwhile, do keep us in mind if you hear anything interesting. Have heart, though. You made it this far, so why not hang on for another couple of days, yes? So grab that cup of stimulation and get started.
Diabetes 203
203 Diabetes 203
203 
MilliporeSigma and ACD/Labs in collaboration to 'shape the future of analytical testing'
Outsourcing Pharma
JANUARY 10, 2024
Informatics software developer supporting R&D, ACD/Labs, has formed a collaboration with MilliporeSigma, the US and Canada Life Science business of Merck KGaA.
80 
STAT+: Pharmalittle: FDA rejects Merck cough medicine; Sanofi abandons an ADC for lung cancer
STAT
DECEMBER 21, 2023
And, as always, do let us know if you hear anything interesting out there. Under the agreement, BioMarin will add three members to its board, conduct a review of its business strategy, and host an investor day in 2024. Here’s hoping you’re firmly on the downslope of doing actual work for the remainder of 2023.
203 
STAT+: Pharmalittle: Chinese drugmakers develop copycat weight loss drugs; SEC eyes supplier of research monkeys
STAT
AUGUST 16, 2023
The middle of the week is upon us. And what better way to make the time fly than to keep busy. Have heart, though. You made it this far, so why not hang on for another couple of days, yes? So grab that cup of stimulation — our flavor today is butter pecan, a household favorite — and get started.
Let's personalize your content